Profile: Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Our SGN-33 is a humanized antibody targeted to the CD33 antigen, which is highly expressed on acute myeloid leukemia, myelodysplastic syndromes and several myeloproliferative disorders. Our SGN-40 is a humanized antibody targeted to the CD40 antigen.
2 Products/Services (Click for related suppliers)
| |||||
• | Drug Conjugates | • | Humanized Monoclonal Antibody |